Frontiers in Oncology | Cancer Immunity and Immunotherapy

Original Research

Published on 12 Dec 2025

Activation of the STING pathway potentiates the antitumor efficacy of doxorubicin in soft-tissue sarcoma

in Cancer Immunity and Immunotherapy

Wonyoung Choi
Gi Yeon Lee
Sun-Young Kong

Frontiers in Oncology

doi 10.3389/fonc.2025.1634503

1,142 views

Original Research

Published on 10 Dec 2025

Improved survival with phosphodiesterase-5 inhibitor use in men with male-predominant cancers: real-world large database study

in Cancer Immunity and Immunotherapy

Daniel Uralov
Sarah R. Harrington
Hani Samarah
Anika S. Walia
Marina Aweeda
Manal U. Mustafa
Parvesh Kumar
Andrew Briskin
Julian Jackson
Eric V. Mastrolonardo

Frontiers in Oncology

doi 10.3389/fonc.2025.1720304

1,352 views

Review

Published on 10 Dec 2025

Interaction of intratumoral microbiota with the tumor immune microenvironment and its impact on cancer progression

in Cancer Immunity and Immunotherapy

Yan Tingting
Zhu Xiaoling
Zhang Yu
Luo Yan
Luo Yang
Shang Xueqin
Tang Shikai

Frontiers in Oncology

doi 10.3389/fonc.2025.1609889

1,245 views
1 citation

Review

Published on 05 Dec 2025

CD39+PD-1+ regulatory T cells in melanoma: key drivers of systemic immunosuppression and prognostic biomarkers

in Cancer Immunity and Immunotherapy

Guanlin Qiao
Hongxia He
Xiaobing Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1724062

1,115 views

Case Report

Published on 05 Dec 2025

Eribulin and sintilimab combined with radiotherapy in a heavily pretreated patient with advanced retroperitoneal myxoid pleomorphic liposarcoma: a case report and literature review

in Cancer Immunity and Immunotherapy

Hongyu Zhuo
Dongna Li
Yang Fu
Xinyao Zhang
Xin He
Ying Xu
Jie Liu
Yu Jiang
Yaotiao Deng

Frontiers in Oncology

doi 10.3389/fonc.2025.1719603

982 views
1 citation

Review

Published on 03 Dec 2025

Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications

in Cancer Immunity and Immunotherapy

Gilad W. Vainer
Sunil S. Badve
Pathmanathan Rajadurai
Fernando A. Soares
Giuseppe Viale
Reinhard Büttner
Shanthy Nuti
Jonathan Juco
Radha Krishnan
Ming-Sound Tsao

Frontiers in Oncology

doi 10.3389/fonc.2025.1581275

1,356 views

Case Report

Published on 28 Nov 2025

Malignant mesothelioma in rare sites: two case reports

in Cancer Immunity and Immunotherapy

Qiguang Du
Jialu Guo
Zi Zhu
Yutong Zhang
He Cui
Zhongkai Xu
Rang Yang
Wenlong Liang

Frontiers in Oncology

doi 10.3389/fonc.2025.1698949

1,598 views

Brief Research Report

Published on 26 Nov 2025

Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer

in Cancer Immunity and Immunotherapy

Naohiro Wakisaka
Makiko Moriyama-Kita
Satoru Kondo
Eiji Kobayashi
Takayoshi Ueno
Yosuke Nakanishi
Kazuhira Endo
Hisashi Sugimoto
Tomokazu Yoshizaki

Frontiers in Oncology

doi 10.3389/fonc.2025.1732480

2,780 views

Original Research

Published on 26 Nov 2025

A CD47 antibody with minimized erythrocyte and thrombocyte toxicities

in Cancer Immunity and Immunotherapy

Min Pei
Xiao-Dong Dai
Xiao-Fan Jiang
Cai-Yi Yuan
Jie Tan
Kai-Feng He
Guo-Jian Liu
Jin-Di Zhu
Huan-Huan Li
Ai-Ling Pan

Frontiers in Oncology

doi 10.3389/fonc.2025.1686180

1,415 views

Case Report

Published on 26 Nov 2025

Ivonescimab for EGFR-mutant lung adenosquamous carcinoma after multiline therapy: A case report

in Cancer Immunity and Immunotherapy

Xiaohua Pan
Jianya Zhang
Chao Ye
Wanhui Zhu
Wenshu Qu

Frontiers in Oncology

doi 10.3389/fonc.2025.1707096

1,899 views

Original Research

Published on 25 Nov 2025

The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma

in Cancer Immunity and Immunotherapy

Soyoung Kim
Ik-Hwan Han
Suin Lee
Sujin Park
Jae-Won Jeon
Hyunsu Bae

Frontiers in Oncology

doi 10.3389/fonc.2025.1698857

1,192 views

Original Research

Published on 25 Nov 2025

Redox phenotype confers T cell-exclusion microenvironment and resistance to immunotherapy by suppressing STING/MDA5 expression and interferon signaling in lung cancers harboring KEAP1/STK11 mutations

in Cancer Immunity and Immunotherapy

Ashish Shrestha
Yangchan Li
Lixia Huang
Shaoli Li
Yanbin Zhou
Jincui Gu
Ziying Lin

Frontiers in Oncology

doi 10.3389/fonc.2025.1676797

1,211 views

Original Research

Published on 24 Nov 2025

Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study

in Cancer Immunity and Immunotherapy

Kun Chen
Bao’e Guo
Rufeng Liu
Juan Wang
Chen Zhang
Guobing Xu

Frontiers in Oncology

doi 10.3389/fonc.2025.1716014

1,134 views

Original Research

Published on 24 Nov 2025

Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective study

in Cancer Immunity and Immunotherapy

Renba Liang
Ling Lei
Xinxiao Li
Fengming Lan
Fangmeng Fu
Teng Zou
Li Ma
Peng Chen
Zhanmei Wang
Jing Jin

Frontiers in Oncology

doi 10.3389/fonc.2025.1704442

1,151 views

Original Research

Published on 21 Nov 2025

Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis

in Cancer Immunity and Immunotherapy

Xiaoting Lin
Peng Liu
Min Jin
Guoyan Qi

Frontiers in Oncology

doi 10.3389/fonc.2025.1646231

1,367 views

Original Research

Published on 21 Nov 2025

Frailty trajectories and their determinants in cancer patients undergoing immunotherapy: a prospective longitudinal study

in Cancer Immunity and Immunotherapy

Wei Zhu
Juan Ji
Yiqun Yang

Frontiers in Oncology

doi 10.3389/fonc.2025.1684827

934 views

Case Report

Published on 20 Nov 2025

Sintilimab combined with chemotherapy in advanced pulmonary epithelioid hemangioendothelioma: a case report and translational insights

in Cancer Immunity and Immunotherapy

Lijun Jing
Huiyun An
Hao Yang
Liming Zhang
Tongyuan Li
Yongming Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1575039

818 views

Systematic Review

Published on 19 Nov 2025

First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs

in Cancer Immunity and Immunotherapy

Zhifang Mao
Zhiyong Zhang
Meijiao Song
Jiaqi He
Jing Zheng
Wenquan Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1709348

1,555 views

Original Research

Published on 18 Nov 2025

First-line immune checkpoint inhibitors combined with chemotherapy in advanced large-cell neuroendocrine carcinoma of the lung: a real-world retrospective study

in Cancer Immunity and Immunotherapy

Beibei Ji
Wei Luan
Rula Sha
Wenxin Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1709544

1,620 views

Correction

Published on 18 Nov 2025

Correction: Case Report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma

in Cancer Immunity and Immunotherapy

Shuanglong Xiong
Chengxiang Yang
Kaiwen Fu
Xingyun Liao
Yao Ding
Kexue Zhou
Li Zhang
Yan Teng
Chunman Wu
Yongsheng Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1730518

612 views

Original Research

Published on 14 Nov 2025

Phytochemical and nanoparticle-based therapeutic potential of Sphaeranthus indicus against hepatocellular carcinoma via cryptomeridiol targeting

in Cancer Immunity and Immunotherapy

Ritika Ravindra Konduskar
Abhinandan R. Patil
Somnath D. Bhinge
Gourav Rameshlal Chawla
Yash Bhagavan Yadav

Frontiers in Oncology

doi 10.3389/fonc.2025.1691905

1,208 views
2 citations

Original Research

Published on 13 Nov 2025

Adjuvant tyrosine kinase inhibitors plus anti-PD-1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection

in Cancer Immunity and Immunotherapy

Jiaxin Li
Yukun Sun
Ziniu Liu
Jianwen Huang
Jian Wu
Yun Huang
Yali Gao
Baomin Chen
Qiang He

Frontiers in Oncology

doi 10.3389/fonc.2025.1710602

2,208 views

Case Report

Published on 12 Nov 2025

Case Report: Accelerated parathyroid adenoma progression and hypercalcemia-driven neurotoxicity following pembrolizumab-based neoadjuvant therapy in triple-negative breast cancer: a case of multisystem immune-related adverse events

in Cancer Immunity and Immunotherapy

Yi Zeng
Yu Sun
Pengfei Qian

Frontiers in Oncology

doi 10.3389/fonc.2025.1607957

1,255 views
1 citation

Systematic Review

Published on 10 Nov 2025

A bibliometric visualization of resistance to lung cancer immunotherapy: a decade of research progress (2014–2024)

in Cancer Immunity and Immunotherapy

Zhuo Yang
Lanlan Yang
Yuli Wang
Xiangyu Ren
Yajing Cui
Yan Li
Jianchun Wu

Frontiers in Oncology

doi 10.3389/fonc.2025.1656967

1,803 views

1,590 articles

articles

Activation of the STING pathway potentiates the antitumor efficacy of doxorubicin in soft-tissue sarcoma

Improved survival with phosphodiesterase-5 inhibitor use in men with male-predominant cancers: real-world large database study

Interaction of intratumoral microbiota with the tumor immune microenvironment and its impact on cancer progression

CD39+PD-1+ regulatory T cells in melanoma: key drivers of systemic immunosuppression and prognostic biomarkers

Eribulin and sintilimab combined with radiotherapy in a heavily pretreated patient with advanced retroperitoneal myxoid pleomorphic liposarcoma: a case report and literature review

Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications

Malignant mesothelioma in rare sites: two case reports

Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer

A CD47 antibody with minimized erythrocyte and thrombocyte toxicities

Ivonescimab for EGFR-mutant lung adenosquamous carcinoma after multiline therapy: A case report

The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma

Redox phenotype confers T cell-exclusion microenvironment and resistance to immunotherapy by suppressing STING/MDA5 expression and interferon signaling in lung cancers harboring KEAP1/STK11 mutations

Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study

Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective study

Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis

Frailty trajectories and their determinants in cancer patients undergoing immunotherapy: a prospective longitudinal study

Sintilimab combined with chemotherapy in advanced pulmonary epithelioid hemangioendothelioma: a case report and translational insights

First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs

First-line immune checkpoint inhibitors combined with chemotherapy in advanced large-cell neuroendocrine carcinoma of the lung: a real-world retrospective study

Correction: Case Report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma

Phytochemical and nanoparticle-based therapeutic potential of Sphaeranthus indicus against hepatocellular carcinoma via cryptomeridiol targeting

Adjuvant tyrosine kinase inhibitors plus anti-PD-1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection

Case Report: Accelerated parathyroid adenoma progression and hypercalcemia-driven neurotoxicity following pembrolizumab-based neoadjuvant therapy in triple-negative breast cancer: a case of multisystem immune-related adverse events

A bibliometric visualization of resistance to lung cancer immunotherapy: a decade of research progress (2014–2024)